+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Idiopathic Pulmonary Fibrosis - Global Market Trajectory & Analytics

  • ID: 5309488
  • Report
  • April 2021
  • Region: Global
  • 126 pages
  • Global Industry Analysts, Inc
Global Idiopathic Pulmonary Fibrosis Market to Reach $4.6 Billion by 2027

Amid the COVID-19 crisis, the global market for Idiopathic Pulmonary Fibrosis estimated at US$2.2 Billion in the year 2020, is projected to reach a revised size of US$4.6 Billion by 2027, growing at a CAGR of 11.1% over the period 2020-2027. PIRFENIDONE, one of the segments analyzed in the report, is projected to record 10.6% CAGR and reach US$2.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the NINTEDANIB segment is readjusted to a revised 11.6% CAGR for the next 7-year period.



The U.S. Market is Estimated at $653.5 Million, While China is Forecast to Grow at 10.7% CAGR

The Idiopathic Pulmonary Fibrosis market in the U.S. is estimated at US$653.5 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$813.5 Million by the year 2027 trailing a CAGR of 10.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.6% and 9.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Select Competitors (Total 42 Featured):
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • Galapagos NV
  • MediciNova, Inc.
  • Merck & Co., Inc.
  • Promedior, Inc.
  • ProMetic Life Sciences, Inc.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for PIRFENIDONE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for PIRFENIDONE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for PIRFENIDONE by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for NINTEDANIB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for NINTEDANIB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for NINTEDANIB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • Table 10: USA Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 11: USA Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 12: USA 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2012, 2020 & 2027
  • Table 13: Canada Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 14: Canada Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 15: Canada 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2012, 2020 & 2027
  • Table 16: Japan Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 17: Japan Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 18: Japan 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2012, 2020 & 2027
  • Table 19: China Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 20: China Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 21: China 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2012, 2020 & 2027
  • Table 22: Europe Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 23: Europe Historic Review for Idiopathic Pulmonary Fibrosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 24: Europe 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 25: Europe Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: Europe Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 27: Europe 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2012, 2020 & 2027
  • Table 28: France Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 29: France Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 30: France 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2012, 2020 & 2027
  • Table 31: Germany Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: Germany Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 33: Germany 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2012, 2020 & 2027
  • Table 34: Italy Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 35: Italy Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 36: Italy 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2012, 2020 & 2027
  • Table 37: UK Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 38: UK Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 39: UK 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2012, 2020 & 2027
  • Table 40: Rest of Europe Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 41: Rest of Europe Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 42: Rest of Europe 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2012, 2020 & 2027
  • Table 43: Asia-Pacific Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 44: Asia-Pacific Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 45: Asia-Pacific 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2012, 2020 & 2027
  • Table 46: Rest of World Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 47: Rest of World Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 48: Rest of World 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 42
Note: Product cover images may vary from those shown
Adroll
adroll